If a variant has more than one submission, it may be counted in more than one significance column. If this is the
case, the total number of variants will be less than the sum of the other cells.
| pathogenic |
likely pathogenic |
uncertain significance |
likely benign |
benign |
not provided |
total |
|
81
|
102
|
239
|
203
|
12
|
1
|
551
|
Condition and significance breakdown #
| Condition |
pathogenic |
likely pathogenic |
uncertain significance |
likely benign |
benign |
not provided |
total |
|
Combined immunodeficiency with skin granulomas; Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-positive
|
65
|
27
|
146
|
193
|
8
|
1
|
439
|
|
Histiocytic medullary reticulosis
|
11
|
4
|
78
|
9
|
11
|
0 |
105
|
|
Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-positive
|
6
|
3
|
35
|
5
|
7
|
0 |
55
|
|
Combined immunodeficiency with skin granulomas
|
15
|
28
|
5
|
0 |
0 |
0 |
47
|
|
not provided
|
8
|
17
|
11
|
6
|
8
|
0 |
47
|
|
Recombinase activating gene 2 deficiency
|
8
|
11
|
18
|
2
|
3
|
0 |
41
|
|
Combined immunodeficiency with skin granulomas; Histiocytic medullary reticulosis; Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-positive
|
6
|
26
|
7
|
2
|
0 |
0 |
39
|
|
Inborn genetic diseases
|
0 |
0 |
26
|
1
|
0 |
0 |
27
|
|
not specified
|
0 |
0 |
15
|
4
|
4
|
0 |
23
|
|
Histiocytic medullary reticulosis; Recombinase activating gene 2 deficiency; Inborn error of immunity
|
0 |
6
|
5
|
0 |
1
|
0 |
12
|
|
RAG2-related disorder
|
3
|
1
|
2
|
4
|
0 |
0 |
10
|
|
Severe combined immunodeficiency disease
|
3
|
5
|
2
|
0 |
0 |
0 |
10
|
|
Recombinase activating gene 2 deficiency; Inborn error of immunity
|
0 |
3
|
2
|
0 |
1
|
0 |
6
|
|
Severe combined immunodeficiency, B cell-negative
|
5
|
1
|
0 |
0 |
0 |
0 |
6
|
|
Histiocytic medullary reticulosis; Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-positive; Recombinase activating gene 2 deficiency; Inborn error of immunity
|
0 |
2
|
3
|
0 |
0 |
0 |
5
|
|
Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-positive; Recombinase activating gene 2 deficiency; Inborn error of immunity
|
0 |
2
|
1
|
1
|
0 |
0 |
4
|
|
Atypical severe combined immunodeficiency due to complete RAG1/2 deficiency; Recombinase activating gene 2 deficiency; Inborn error of immunity
|
1
|
0 |
2
|
0 |
0 |
0 |
3
|
|
Combined immunodeficiency with skin granulomas; Recombinase activating gene 2 deficiency; Inborn error of immunity
|
0 |
2
|
1
|
0 |
0 |
0 |
3
|
|
Common variable immunodeficiency
|
2
|
0 |
0 |
0 |
0 |
0 |
2
|
|
Combined immunodeficiency with skin granulomas; Histiocytic medullary reticulosis; Atypical severe combined immunodeficiency due to complete RAG1/2 deficiency; Recombinase activating gene 2 deficiency; Inborn error of immunity
|
0 |
1
|
0 |
0 |
0 |
0 |
1
|
|
Histiocytic medullary reticulosis; Atypical severe combined immunodeficiency due to complete RAG1/2 deficiency; Recombinase activating gene 2 deficiency; Inborn error of immunity
|
0 |
1
|
0 |
0 |
0 |
0 |
1
|
|
Immunodeficiency 104
|
0 |
0 |
1
|
0 |
0 |
0 |
1
|
|
Salla disease
|
0 |
1
|
0 |
0 |
0 |
0 |
1
|
Submitter and significance breakdown #
| Submitter |
pathogenic |
likely pathogenic |
uncertain significance |
likely benign |
benign |
not provided |
total |
|
Labcorp Genetics (formerly Invitae), Labcorp
|
65
|
27
|
146
|
193
|
8
|
0 |
439
|
|
Natera, Inc.
|
7
|
2
|
52
|
5
|
7
|
0 |
73
|
|
Baylor Genetics
|
14
|
29
|
3
|
0 |
0 |
0 |
46
|
|
Illumina Laboratory Services, Illumina
|
0 |
0 |
31
|
4
|
7
|
0 |
42
|
|
ClinGen Severe Combined Immunodeficiency Variant Curation Expert Panel, ClinGen
|
7
|
11
|
18
|
2
|
3
|
0 |
41
|
|
Pediatric Immunology Service, The Chaim Sheba Medical Center at Tel HaShomer
|
1
|
17
|
14
|
1
|
2
|
0 |
35
|
|
Fulgent Genetics, Fulgent Genetics
|
6
|
24
|
3
|
0 |
0 |
0 |
33
|
|
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
|
4
|
6
|
15
|
3
|
2
|
0 |
30
|
|
Ambry Genetics
|
0 |
0 |
26
|
1
|
0 |
0 |
27
|
|
GeneDx
|
5
|
7
|
2
|
2
|
8
|
0 |
24
|
|
PreventionGenetics, part of Exact Sciences
|
3
|
1
|
2
|
4
|
1
|
0 |
11
|
|
OMIM
|
10
|
0 |
0 |
0 |
0 |
0 |
10
|
|
Genomic Medicine Center of Excellence, King Faisal Specialist Hospital and Research Centre
|
1
|
6
|
2
|
0 |
0 |
0 |
9
|
|
Breakthrough Genomics, Breakthrough Genomics
|
0 |
0 |
1
|
3
|
5
|
0 |
9
|
|
CeGaT Center for Human Genetics Tuebingen
|
2
|
2
|
0 |
3
|
1
|
0 |
8
|
|
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
|
1
|
0 |
2
|
1
|
3
|
0 |
7
|
|
Genome-Nilou Lab
|
0 |
1
|
4
|
0 |
1
|
0 |
6
|
|
Department of Pathology and Laboratory Medicine, Sinai Health System
|
0 |
1
|
3
|
1
|
0 |
0 |
5
|
|
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
|
0 |
0 |
2
|
2
|
0 |
0 |
4
|
|
Genome Diagnostics Laboratory, University Medical Center Utrecht
|
0 |
0 |
0 |
3
|
0 |
0 |
3
|
|
Counsyl
|
0 |
1
|
1
|
1
|
0 |
0 |
3
|
|
Mayo Clinic Laboratories, Mayo Clinic
|
0 |
0 |
3
|
0 |
0 |
0 |
3
|
|
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
|
0 |
0 |
2
|
0 |
1
|
0 |
3
|
|
Revvity Omics, Revvity
|
1
|
1
|
0 |
0 |
0 |
0 |
2
|
|
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute
|
1
|
0 |
0 |
1
|
0 |
0 |
2
|
|
Blueprint Genetics
|
0 |
2
|
0 |
0 |
0 |
0 |
2
|
|
NIHR Bioresource Rare Diseases, University of Cambridge
|
2
|
0 |
0 |
0 |
0 |
0 |
2
|
|
Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago
|
0 |
0 |
2
|
0 |
0 |
0 |
2
|
|
Seattle Children's Hospital Molecular Genetics Laboratory, Seattle Children's Hospital
|
1
|
1
|
0 |
0 |
0 |
0 |
2
|
|
Intergen, Intergen Genetics and Rare Diseases Diagnosis Center
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
|
Mendelics
|
0 |
0 |
0 |
1
|
0 |
0 |
1
|
|
Eurofins Ntd Llc (ga)
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
|
Genomic Research Center, Shahid Beheshti University of Medical Sciences
|
0 |
0 |
1
|
0 |
0 |
0 |
1
|
|
Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital
|
0 |
0 |
0 |
0 |
1
|
0 |
1
|
|
Center for Personalized Medicine, Children's Hospital Los Angeles
|
0 |
1
|
0 |
0 |
0 |
0 |
1
|
|
Kariminejad - Najmabadi Pathology & Genetics Center
|
0 |
1
|
0 |
0 |
0 |
0 |
1
|
|
Laboratory of Pediatric Immunoinfectivology, Tor Vergata University
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
|
Genomics Facility, Ludwig-Maximilians-Universität München
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
|
UOSD Laboratory of Genetics & Genomics of Rare Diseases, Istituto Giannina Gaslini
|
0 |
0 |
1
|
0 |
0 |
0 |
1
|
|
3billion
|
0 |
0 |
1
|
0 |
0 |
0 |
1
|
|
GenomeConnect - Invitae Patient Insights Network
|
0 |
0 |
0 |
0 |
0 |
1
|
1
|
|
Neuberg Centre For Genomic Medicine, NCGM
|
0 |
0 |
1
|
0 |
0 |
0 |
1
|
|
GreenArray Genomic Research & Solutions of Accurate Diagnostic Private Limited
|
0 |
0 |
1
|
0 |
0 |
0 |
1
|
|
Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
|
Laboratory of Hereditary Immune Disorders, Research Centre for Medical Genetics
|
1
|
0 |
0 |
0 |
0 |
0 |
1
|
The information on this website is not intended for direct
diagnostic use or medical decision-making without review by a
genetics professional. Individuals should not change their
health behavior solely on the basis of information contained on
this website. Neither the University of Utah nor the National
Institutes of Health independently verfies the submitted
information. If you have questions about the information
contained on this website, please see a health care
professional.